Skip to main content

In Brief This Week: Immunovia, MNG Laboratories, Flagship Biosciences, and More

NEW YORK (360Dx) – Immunovia said that the NYU School of Medicine has joined PanFAM-1, a prospective study investigating early diagnosis in high-risk individuals with familial pancreatic cancer. The study is designed to validate Immunovia’s blood test, IMMray PanCan-d, and will analyze more than 1,000 individuals over three years across sites in the US and Europe. Other participants in PanFAM-1 include Mount Sinai in New York; Knight Cancer Institute at Oregon Health and Sciences University, the University of Pittsburgh Medical Center; Massachusetts General Hospital; the University of Liverpool, UK; Ramon y Cajal Institute for Health Research in Spain; University Hospital of Santiago de Compostela in Spain; and Sahlgrenska University Hospital in Sweden.


MNG Laboratories announced this week that it has signed several international distribution agreements for its products in Asia, Latin America, and Eastern Europe. MNG now has active distributors for its menu of more than 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey, and Chile. Each distributor was chosen for their clinical expertise, customer service, and technical leadership in their respective markets. MNG did not name the individual distributors.


Flagship Biosciences has received accreditation from the College of American Pathologists that covers all common laboratory services, anatomic pathology processing, and digital image analysis. Based in Westminster, Colorado, Flagship uses its Computational Tissue Analytics (cTA) and data-driven decision support platform to provide quantitative and contextual tissue analysis.


Sysmex Inostics said this week that colorectal cancer patients in Germany insured by public insurance fund Barmer are now covered for the firm's OncoBEAM RAS CRC IVD Test, a liquid biopsy diagnostic that evaluates a patient's RAS mutations from a single tube of blood.


Bioscience Genomics and the Institute of Pathology of University Hospital Basel have signed a memorandum of understanding to establish a solid cancer prevention program that will use Bioscience Genomics' technology to help manage solid cancer prodromal stage assessments. Bioscience Genomics is a spinout of the University of Rome Tor Vergata and Bioscience Institute and has developed a proprietary technology called Helifaxe that employs proprietary algorithms and other tools to measure and monitor the frequency of somatic mutations and to assess genetic stability.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.